What is it about?
Neovascular glaucoma (NVG) poses a tremendous challenge in its management. This paper evaluates if there is any hope of better outcome with the use of intravitreal anti-VEGF in combination with surgery. We have shown that glaucoma drainage device (GDD) combined with intravitreal bevacizumab (IVB) could maintain visual acuity compared to GDD alone.
Featured Image
Why is it important?
Our findings show that intravitreal anti-VEGF injection might be beneficial as an adjunctive treatment in NVG cases along with glaucoma drainage device implantation. Further investigation is required to confirm this benefit.
Perspectives
I hope this article can lead to further investigation and invention in the management of neovascular glaucoma, so that both patients and clinicians have treatment options which lead to better prognosis. Writing this paper was also a great pleasure as I was working in good collaborations with co-authors.
Nina Asrini Noor
Jakarta Eye Center
Read the Original
This page is a summary of: Glaucoma drainage device implantation with adjunctive intravitreal bevacizumab in neovascular glaucoma: 3-year experience, Clinical Ophthalmology, August 2017, Dove Medical Press,
DOI: 10.2147/opth.s137470.
You can read the full text:
Contributors
The following have contributed to this page
